Three Drug Classes Compared for Cardiovascular and Kidney Benefits in Diabetes
Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in diabetes evaluates which drug class provides optimal organ protection.
Quick Facts
What This Study Found
Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in diabetes evaluates which drug class provides optimal organ protection.
Key Numbers
Network meta-analysis through December 2024 comparing three drug classes across cardiovascular and renal endpoints in T2D.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.
- Published In:
- World journal of diabetes, 16(11), 111280 (2025)
- Authors:
- An, Xue-Dong, Li, Xin-Qin, Zhang, He, Jia, Qian-You, Zhang, Yue-Hong, Yang, Gui-Gui
- Database ID:
- RPEP-09934
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Comparison of GLP-1 drugs, SGLT2 inhibitors, and finerenone for cardiovascular and renal benefits in diabetes evaluates which drug class provides optimal organ protection.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09934APA
An, Xue-Dong; Li, Xin-Qin; Zhang, He; Jia, Qian-You; Zhang, Yue-Hong; Yang, Gui-Gui. (2025). Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.. World journal of diabetes, 16(11), 111280. https://doi.org/10.4239/wjd.v16.i11.111280
MLA
An, Xue-Dong, et al. "Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.." World journal of diabetes, 2025. https://doi.org/10.4239/wjd.v16.i11.111280
RethinkPeptides
RethinkPeptides Research Database. "Comparison of three types of drugs for cardiovascular and re..." RPEP-09934. Retrieved from https://rethinkpeptides.com/research/an-2025-comparison-of-three-types
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.